( G , H ) Representative Western blots and quantification of p53 (normalized to -actin) in NMCMs treated with or without the JNK inhibitor SP600125 (10 M) for 30 min followed by transfection with control siRNA or Mc5r targeting siRNA for 24 h
Clinical trials and FDA labeling have not identified nephrolithiasis as a recognized adverse effect of semaglutide therapy
Based on the technical problems in the prior art, a synthesis method of semaglutide, which is simple and convenient to operate, low in synthesis cost, higher in efficiency and higher in product purity and is more suitable for industrial production, is urgently needed
While highly effective, this medication can cause gastrointestinal side effects due to its mechanism of slowing gastric emptying
Meet the team Our qualified team of doctors, nurses, nutritionists and pharmacists